Scholarlink

Background <p>Recurrent weight gain after laparoscopic sleeve gastrectomy (LSG) is common. Revisional endoscopic sleeve gastroplasty (r-ESG) has been shown to be a promising endoscopic bariatric therapy (EBT) to treat weight recurrence after LSG. However, to date, weight loss outcomes beyond 1-year follow-up are unknown. Our study aims as follows: (1) examine 1&#xa0;year, 18-month, and 24-month weight loss outcomes post-r-ESG and (2) determine if weight loss outcomes post-LSG predict clinical outcomes post-r-ESG.</p> Methods <p>This was a retrospective cohort data of patients who completed r-ESG from December 2020 to November 2023. The primary outcome was percentage of total body weight loss (TBWL) at 1-year post-r-ESG. Secondary outcomes included TBWL at 18- and 24-month post-r-ESG. Multivariable logistic regression analysis was used to determine predictors of weight loss ≥ 5% at 12&#xa0;months.</p> Results <p>A total of 55 patients completed r-ESG. TBWL post-r-ESG at 12&#xa0;months was 8.6% (<i>n</i> = 37), at 18&#xa0;months was 10.7% (<i>n</i> = 31), and at 24&#xa0;months was 12.6% (<i>n</i> = 18) (Table&#xa0;<InternalRef RefID="Tab2">2</InternalRef>). There were no statistically significant variables associated with weight loss ≥ 5% at 12&#xa0;months (Table&#xa0;<InternalRef RefID="Tab3">3</InternalRef>).</p> Conclusions <p>Our study demonstrates that r-ESG is an effective and durable EBT for post-LSG weight recurrence. Further research is needed to determine optimal timing of r-ESG for weight recurrence as well as the adjunctive role of anti-obesity medications<b>.</b></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of Revisional Endoscopic Sleeve Gastroplasty After Laparoscopic Sleeve Gastrectomy

  • 期刊论文

  • 发表日期：

    2025年1月8日

查看全文
  • John Deng,
  • Julia Wool,
  • Ronald Blanco Montecino,
  • Alvaro Cadillo Arbaiza,
  • Luyu Xie,
  • Sarah E. Messiah,
  • Sunil Matthew,
  • Shannon Shiffer,
  • Jaime P. Almandoz,
  • Anna Tavakkoli

摘要

Background

Recurrent weight gain after laparoscopic sleeve gastrectomy (LSG) is common. Revisional endoscopic sleeve gastroplasty (r-ESG) has been shown to be a promising endoscopic bariatric therapy (EBT) to treat weight recurrence after LSG. However, to date, weight loss outcomes beyond 1-year follow-up are unknown. Our study aims as follows: (1) examine 1 year, 18-month, and 24-month weight loss outcomes post-r-ESG and (2) determine if weight loss outcomes post-LSG predict clinical outcomes post-r-ESG.

Methods

This was a retrospective cohort data of patients who completed r-ESG from December 2020 to November 2023. The primary outcome was percentage of total body weight loss (TBWL) at 1-year post-r-ESG. Secondary outcomes included TBWL at 18- and 24-month post-r-ESG. Multivariable logistic regression analysis was used to determine predictors of weight loss ≥ 5% at 12 months.

Results

A total of 55 patients completed r-ESG. TBWL post-r-ESG at 12 months was 8.6% (n = 37), at 18 months was 10.7% (n = 31), and at 24 months was 12.6% (n = 18) (Table 2). There were no statistically significant variables associated with weight loss ≥ 5% at 12 months (Table 3).

Conclusions

Our study demonstrates that r-ESG is an effective and durable EBT for post-LSG weight recurrence. Further research is needed to determine optimal timing of r-ESG for weight recurrence as well as the adjunctive role of anti-obesity medications.